FOXA1 promotes tumor progression in prostate cancer and represents a novel hallmark of castration-resistant prostate cancer
- PMID: 22138582
- DOI: 10.1016/j.ajpath.2011.10.021
FOXA1 promotes tumor progression in prostate cancer and represents a novel hallmark of castration-resistant prostate cancer
Abstract
Forkhead box protein A1 (FOXA1) modulates the transactivation of steroid hormone receptors and thus may influence tumor growth and hormone responsiveness in prostate cancer. We therefore investigated the correlation of FOXA1 expression with clinical parameters, prostate-specific antigen (PSA) relapse-free survival, and hormone receptor expression in a large cohort of prostate cancer patients at different disease stages. FOXA1 expression did not differ significantly between benign glands from the peripheral zone and primary peripheral zone prostate carcinomas. However, FOXA1 was overexpressed in metastases and particularly in castration-resistant cases, but was expressed at lower levels in both normal and neoplastic transitional zone tissues. FOXA1 levels correlated with higher pT stages and Gleason scores, as well as with androgen (AR) and estrogen receptor expression. Moreover, FOXA1 overexpression was associated with faster biochemical disease progression, which was pronounced in patients with low AR levels. Finally, siRNA-based knockdown of FOXA1 induced decreased cell proliferation and migration. Moreover, in vitro tumorigenicity was inducible by ARs only in the presence of FOXA1, substantiating a functional cooperation between FOXA1 and AR. In conclusion, FOXA1 expression is associated with tumor progression, dedifferentiation of prostate cancer cells, and poorer prognosis, as well as with cellular proliferation and migration and with AR signaling. These findings suggest FOXA1 overexpression as a novel mechanism inducing castration resistance in prostate cancer.
Copyright © 2012 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Modulation of androgen receptor by FOXA1 and FOXO1 factors in prostate cancer.Int J Biol Sci. 2014 Jun 5;10(6):614-9. doi: 10.7150/ijbs.8389. eCollection 2014. Int J Biol Sci. 2014. PMID: 24948874 Free PMC article. Review.
-
Forkhead-box A1 transcription factor is a novel adverse prognosis marker in human glioma.J Clin Neurosci. 2013 May;20(5):654-8. doi: 10.1016/j.jocn.2012.03.055. Epub 2013 Mar 16. J Clin Neurosci. 2013. PMID: 23510544
-
FOXA1: a transcription factor with parallel functions in development and cancer.Biosci Rep. 2012 Apr 1;32(2):113-30. doi: 10.1042/BSR20110046. Biosci Rep. 2012. PMID: 22115363 Free PMC article. Review.
-
Peroxiredoxin 2 in the nucleus and cytoplasm distinctly regulates androgen receptor activity in prostate cancer cells.Free Radic Biol Med. 2011 Jul 1;51(1):78-87. doi: 10.1016/j.freeradbiomed.2011.04.001. Epub 2011 Apr 14. Free Radic Biol Med. 2011. PMID: 21539911
-
Expression and role of Foxa proteins in prostate cancer.Prostate. 2006 Jul 1;66(10):1013-28. doi: 10.1002/pros.20299. Prostate. 2006. PMID: 16001449
Cited by
-
From molecular mechanisms of prostate cancer to translational applications: based on multi-omics fusion analysis and intelligent medicine.Health Inf Sci Syst. 2023 Dec 18;12(1):6. doi: 10.1007/s13755-023-00264-5. eCollection 2024 Dec. Health Inf Sci Syst. 2023. PMID: 38125666 Review.
-
A Druggable FOXA1-Glucocorticoid Receptor Transcriptional Axis Drives Tumor Growth in a Subset of Non-Small Cell Lung Cancer.Cancer Res Commun. 2023 Sep 7;3(9):1788-1799. doi: 10.1158/2767-9764.CRC-23-0310. eCollection 2023 Sep. Cancer Res Commun. 2023. PMID: 37691854 Free PMC article.
-
Cellular specificity of androgen receptor, coregulators, and pioneer factors in prostate cancer.Endocr Oncol. 2022 Sep 8;2(1):R112-R131. doi: 10.1530/EO-22-0065. eCollection 2022 Jan. Endocr Oncol. 2022. PMID: 37435460 Free PMC article. Review.
-
A role for androgen receptor variant 7 in sensitivity to therapy: Involvement of IGFBP-2 and FOXA1.Transl Oncol. 2023 Aug;34:101698. doi: 10.1016/j.tranon.2023.101698. Epub 2023 Jun 10. Transl Oncol. 2023. PMID: 37307644 Free PMC article.
-
TRAF4-mediated nonproteolytic ubiquitination of androgen receptor promotes castration-resistant prostate cancer.Proc Natl Acad Sci U S A. 2023 May 16;120(20):e2218229120. doi: 10.1073/pnas.2218229120. Epub 2023 May 8. Proc Natl Acad Sci U S A. 2023. PMID: 37155905 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous